Literature DB >> 8274756

Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium.

P N Correa1, D Eskinazi, A A Axelrad.   

Abstract

We have investigated the question of erythropoietin (Epo) hypersensitivity versus Epo independence as the basis for the endogenous erythroid bursts (EEBs) that develop in cultures without added Epo from hematopoietic cells of polycythemia vera (PV) patients. Using an improved serum-free (SF) medium containing interleukin (IL)-3, but no insulin-like growth factor-1 (IGF-1), and devoid of contaminants that influence erythropoiesis, we compared circulating normal and PV early erythroid progenitors (BFU-E) with respect to their responses in vitro to recombinant human (rHu) Epo. Cultures were seeded with Ficoll-Hypaque density-separated peripheral blood (PB) mononuclear cells (MNCs), and erythroid bursts, together with their component colonies of > or = 50 cells, were scored in situ at 13 to 16 days of culture. The Epo dose-response curve of BFU-E from PV patients was found to be statistically indistinguishable from that of normal subjects. This observation provides compelling evidence against the Epo-hypersensitivity hypothesis. In the complete SF medium minus Epo, the sensitivity of BFU-E to IGF-1 was much greater in PV than in normals, the dose-response curve being shifted to the left by at least 2 orders of magnitude. These data show that the erythroid progenitor cell response in PV is hypersensitive to IGF-1, and independent of Epo. The data also emphasize the importance of truly SF medium conditions for assessment of progenitor cell sensitivities to recombinant growth factors. Depletion of adherent cells totally prevented erythroid burst formation by normal circulating progenitors, but did not prevent the hypersensitive response to IGF-1 of such cells from PV patients. Hence, again unlike its normal counterpart, the progenitor cell response in PV appears to be independent of adherent cell control.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8274756

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Basic sciences of the myeloproliferative diseases: pathogenic mechanisms of ET and PV.

Authors:  Rosemary E Gale
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  INSULIN-LIKE GROWTH FACTOR-1 AND ANEMIA IN OLDER SUBJECTS: THE INCHIANTI STUDY.

Authors:  Francesca De Vita; Marcello Maggio; Fulvio Lauretani; Lara Crucitti; Stefania Bandinelli; Federica Mammarella; Francesco Landi; Luigi Ferrucci; Gian Paolo Ceda
Journal:  Endocr Pract       Date:  2015-07-27       Impact factor: 3.443

3.  Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway.

Authors:  Wei Zhao; Claire Kitidis; Mark D Fleming; Harvey F Lodish; Saghi Ghaffari
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

4.  Idiopathic erythrocytosis in IgA nephropathy.

Authors:  E Mahesh; P R Madhyastha; M Kalashetty; K C Gurudev; S Bande; M M John
Journal:  Indian J Nephrol       Date:  2017 Jan-Feb

Review 5.  Polycythemia vera--a climatological disease.

Authors:  N I Berlin
Journal:  Trans Am Clin Climatol Assoc       Date:  1995

Review 6.  The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.

Authors:  Martha Wadleigh; D Gary Gilliland
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

Review 7.  The pathogenesis of chronic myeloproliferative diseases.

Authors:  A Tefferi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

8.  JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.

Authors:  Sven Schwemmers; Britta Will; Cornelius F Waller; Khadija Abdulkarim; Peter Johansson; Björn Andreasson; Heike L Pahl
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

9.  CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy.

Authors:  Kathleen M Sakamoto; David A Frank
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

10.  Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice.

Authors:  R J D'Andrea; D Harrison-Findik; C M Butcher; J Finnie; P Blumbergs; P Bartley; M McCormack; K Jones; R Rowland; T J Gonda; M A Vadas
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.